Online inquiry

IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9300MR)

This product GTTS-WQ9300MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets HLA gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001242524.2;
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3113; 3108; 3111; 3117; 3123
UniProt ID Q30058; P28067; P28068; P06340; P13765; O19764; E1ACV6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9300MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ752MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AAB-001
GTTS-WQ11460MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ2835MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG-403
GTTS-WQ11868MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MLN-0264
GTTS-WQ15502MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA UCB-7665
GTTS-WQ9457MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IPH4102
GTTS-WQ4345MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BIW-8405
GTTS-WQ13969MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.